Alnylam Pharmaceuticals shares have taken a hit following its latest earnings report, but RBC Capital Markets believes the selloff may have gone too far. The investment bank trimmed its price target on the biotech to $350, citing a softer quarter and lower full-year guidance for its transthyretin (TTR) franchise. Yet RBC also highlighted reasons for optimism, including growth of its drug Amvuttra and progress across its pipeline.
What happened with Alnylam's earnings?
Alnylam, a company focused on RNA interference (RNAi) therapeutics, reported quarterly results that came in below expectations. The company also reduced its guidance for transthyretin-related revenue, which includes sales of its drugs Amvuttra and Onpattro. Transthyretin amyloidosis is a rare, progressive disease that can affect the heart and nerves, and it is a key focus for Alnylam.
The softer quarter and the guidance cut weighed on investor sentiment, sending the stock lower. But RBC argues that the market's reaction may be too harsh, given the underlying strengths it sees in the business.
Why RBC thinks the dip is overdone
RBC's new price target of $350 is lower than its previous target, but it still implies meaningful upside from current levels. The bank points to continued growth of Amvuttra, which is approved for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis. Amvuttra has been seen as a key growth driver for Alnylam, and RBC expects that momentum to continue.
In addition, RBC notes progress across Alnylam's pipeline, which includes potential treatments for other diseases. The company has been expanding its RNAi platform beyond transthyretin amyloidosis, targeting conditions like hypertension, hemophilia, and other rare diseases. Pipeline advances could provide new revenue streams and diversify the company's portfolio.
What this means for investors
For everyday investors, the key takeaway is that analyst views can vary even after a disappointing earnings report. While RBC lowered its price target, it still sees value in Alnylam's shares. The stock's drop may reflect near-term concerns, but the longer-term story could remain intact if Amvuttra keeps growing and the pipeline delivers.
It's also worth noting that biotech stocks are often volatile, especially around earnings and clinical data readouts. A single quarter's miss or guidance cut can trigger sharp moves, but it doesn't necessarily change the fundamental outlook for a company with a strong product portfolio and pipeline.
Investors should consider their own risk tolerance and investment horizon. Alnylam's story is not without risks—competition, regulatory hurdles, and the inherent uncertainty of drug development all remain. But for those who believe in the company's long-term potential, the post-earnings dip might present an opportunity, as RBC suggests.
Broader market context
The biotech sector has been under pressure in recent months as investors rotate toward other areas, such as technology and AI-related stocks. Amazon and Microsoft earnings have revived investor appetite for AI stocks, drawing attention away from biotech. However, that doesn't mean biotech is without opportunities. Companies with strong pipelines and commercial execution can still attract interest.
Alnylam's situation is also reminiscent of other companies that have seen their stocks dip after guidance cuts, only to recover later if the underlying business remains healthy. Berenberg trimmed Saint-Gobain's target but kept a buy rating, a similar pattern of cautious optimism. And Barclays noted Enel's first-half beat supports its 2026 plan, showing how analysts weigh near-term results against longer-term goals.
What to watch next
Investors will likely keep an eye on Alnylam's commercial execution, especially Amvuttra's sales trajectory. The company's pipeline milestones, including clinical trial readouts and regulatory updates, will also be important. Any news on new indications or expansion into additional markets could provide catalysts.
RBC's stance suggests that the selloff may be overdone, but that doesn't mean the stock will rebound immediately. Biotech investing requires patience and a tolerance for volatility. As always, it's wise to do your own research and consider how a stock fits into your overall portfolio.
This article is for informational purposes only and does not constitute investment advice. Always consult a financial professional before making investment decisions.
